Mavacamten Demonstrated Significant Reduction in Need for Septal Reduction Therapy in Symptomatic Obstructive HCM Patients in Phase 3 VALOR Trial - InvestingNews.com

Mavacamten is a first-in-class, investigational cardiac myosin inhibitor being developed by Bristol Myers Squibb Study met all primary and secondary endpoints and patients receiving mavacamten demonstrated improvement in key cardiac measures after 16 we…

Mavacamten is a first-in-class, investigational cardiac myosin inhibitor being developed by Bristol Myers Squibb Study met all primary and secondary endpoints and patients receiving mavacamten dem… [+13389 chars]

full article...